Pyxis Oncology (PYXS) Amortizatization of Intangibles (2023 - 2025)
Pyxis Oncology (PYXS) posted quarterly Amortizatization of Intangibles of $375000.0 for Q4 2025, down 75.54% year-over-year from $1.5 million in Q4 2024, and down 29.51% quarter-over-quarter from $532000.0 in Q3 2025.
Pyxis Oncology (PYXS) Amortizatization of Intangibles (2023 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has reported Amortizatization of Intangibles for 3 consecutive years, with $375000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Amortizatization of Intangibles fell 75.54% year-over-year to $375000.0; the TTM figure through Dec 2025 stood at $3.0 million (down 51.55% YoY), while the FY2025 annual figure was $3.0 million, down 51.55% from the prior year.
- Amortizatization of Intangibles slipped to $375000.0 in Q4 2025 per PYXS's latest filing, from $532000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $1.7 million in Q3 2024 and bottomed at $375000.0 in Q4 2025.
- Historically, Amortizatization of Intangibles has averaged $1.2 million across 3 years, with a median of $1.3 million in 2023.
- Annual changes were most pronounced in 2024 — Amortizatization of Intangibles soared 112.19% — and 2025, when it plunged 75.54%.
- Pyxis Oncology's Amortizatization of Intangibles stood at $1.4 million in 2023, then climbed by 6.38% to $1.5 million in 2024, then slumped by 75.54% to $375000.0 in 2025.
- Business Quant data shows PYXS's Amortizatization of Intangibles at $375000.0 in Q4 2025, $532000.0 in Q3 2025, and $896000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Pyxis Oncology | 198.37 Mn | 165.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 375,000.00 |
| Dec 31, 2025 | 375,000.00 |
| Sep 30, 2025 | 532,000.00 |
| Sep 30, 2025 | 532,000.00 |
| Jun 30, 2025 | 896,000.00 |
| Jun 30, 2025 | 896,000.00 |
| Mar 31, 2025 | 1.16 Mn |
| Mar 31, 2025 | 1.16 Mn |
| Dec 31, 2024 | 1.53 Mn |
| Dec 31, 2024 | 1.53 Mn |
| Sep 30, 2024 | 1.65 Mn |
| Sep 30, 2024 | 1.65 Mn |
| Jun 30, 2024 | 1.64 Mn |
| Jun 30, 2024 | 1.64 Mn |
| Mar 31, 2024 | 1.29 Mn |
| Mar 31, 2024 | 1.29 Mn |
| Dec 31, 2023 | 1.44 Mn |
| Dec 31, 2023 | 1.44 Mn |
| Sep 30, 2023 | 1.48 Mn |
| Sep 30, 2023 | 1.48 Mn |